Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

Background & Aims: This study aimed to assess the changes in platelet counts of patients with liver cirrhosis due to chronic HCV, who achieved sustained virological response (SVR) after taking direct acting antivirals (DAAs) in a large cohort study in Egypt. Methods: This multicenter observational retrospective study was carried out on 2500 chronic hepatitis C virus (HCV) infected patients who achieved (SVR) after treatment with direct acting antiviral drugs (DAA). HCV infection was confirmed by positive PCR for HCV RNA infection. SVR was defined as a negative PCR test for HCV-RNA 12 weeks after completion of DAA therapy. Platelets count was measured before therapy, during therapy, at the end of treatment, and 12 weeks after the end of the treatment. Results: There were 2186 patients enrolled in the study; 1866 (85.4%) were treatment naïve. There were 1006 (46%) males and 1180 (54%) females. Mean age was 50.82± 11.66 years, 2142 (98 %.0) patients achieved SVR, 2118 (96.9%) patients had Child -Pugh class A cirrhosis, and 68 (3.1%) had Child -Pugh class B liver cirrhosis. A significant increase of the platelets count was detected at the end of treatment in comparison to the pretreatment levels (P<0.001), and after achieving SVR (P <0.001) when compared to the pretreatment values. Conclusion: Improvement of platelets count occurs after HCV therapy with DAAS in patients with liver cirrhosis. These results suggested that HCV eradication may have a role in improvement of platelet count.

Download Full-text

High sustained virological response in difficult to treat hepatitis C patients by combination of daily high dose and prolonged maintenance interferon-ribavirin therapy

Journal of Hepatology ◽

10.1016/s0168-8278(01)81470-7 ◽

2001 ◽

Vol 34 ◽

pp. 163

Author(s):

F.C. Bekkering ◽

J.T. Brouwer ◽

B.E. Hansen ◽

H.G.M. Niesters ◽

S.W. Schalm

Keyword(s):

Hepatitis C ◽

Sustained Virological Response ◽

Virological Response ◽

High Dose ◽

High Sustained Virological Response

Download Full-text

High Sustained Virological Response Rates Using Generic Direct Acting Antiviral Treatment for Hepatitis C, Imported into Australia

Journal of Hepatology ◽

10.1016/s0168-8278(16)01726-8 ◽

2016 ◽

Vol 64 (2) ◽

pp. S209 ◽

Cited By ~ 13

Author(s):

J. Freeman ◽

R. Sallie ◽

A. Kennedy ◽

P.T.N. Hieu ◽

J. Freeman ◽

...

Keyword(s):

Hepatitis C ◽

Sustained Virological Response ◽

Virological Response ◽

Antiviral Treatment ◽

Response Rates ◽

Direct Acting Antiviral ◽

Direct Acting ◽

High Sustained Virological Response

Download Full-text

Assessment of Doppler haemodynamic changes suggestive of portal hypertension in cirrhotic HCV patients after sustained virological response to direct antiviral agents

QJM ◽

10.1093/qjmed/hcab100.024 ◽

2021 ◽

Vol 114 (Supplement_1) ◽

Author(s):

Mennatullah M Ezzat ◽

Sara M Abdelhakam ◽

Amira M Al-Balakosy ◽

Ahmed A Ghalwash

Keyword(s):

Portal Hypertension ◽

Sustained Virological Response ◽

Virological Response ◽

Antiviral Agents ◽

Liver Stiffness ◽

University Hospital ◽

Core Antigen ◽

Hcv Rna ◽

Haemodynamic Changes ◽

Direct Antiviral Agents

Abstract Background Egypt has the highest prevalence rate of HCV in the world. About 14.7% of the Egyptian people have HCV antibodies and 9.8% have an active infection. The death rate due to liver disease about 40,000 each year (near10% of all deaths). It is the second after the cardiac diseases. Aim of Work to assess Doppler haemodynamic changes suggestive of portal hypertension in cirrhotic HCV Egyptian patients after sustained virological response to direct antiviral agents, and their correlation with liver stiffness measurements by Fibroscan. Patients and Methods This prospective cohort study was conducted at Viral Hepatitis Unit at Ain Shams University Hospital and Al-Agouza Police Hospital during the period from May 2018 to July 2019. The study included 50 Egyptian treatment-naïve chronic hepatitis C patients with cirrhosis on Sofosbuvir, Daclatasvir for 12 weeks. Patients were subjected to history and full physical examination, radiology assessment (Abdominal Ultrasound and color Doppler), Upper GI endoscopy and Fibroscan before treatment and 6 months after treatment. Followed up with CBC, AST, ALT, Total bilirubin, Albumin, creatinine and Coagulation profile before and after 12 weeks of treatment And HCV RNA by PCR and HCV CORE Antigen before and then after 12 weeks of treatment. Results Treatment with sofosbuvir plus Daclatasvir for 12weeks resulted in undetectable HCV RNA by PCR in 100% of the patients at the end of treatment. There was a significant improvement in portal hemodynamics 6 months after treatment as well as a significant correlation between Doppler indices and fibroscan. Conclusion: Doppler portal hypertensive parameters, as a marker of portal hypertension, were improved in parallel with the improvement in fibroscan values after viral clearance and its improvement in the current study mandate urgent treatment to avoid possible complications.

Download Full-text